Analysis of Potential Siponimod Launch, Market Positioning and Forecasted Sales -2017
Market Research Hub (MRH) has added a freshly complied report on the Siponimod launch to its vast database. After Siponimod (code name BAF312) gained momentum in phase III trial, speculations are being made that the drug is in its final approval stages and will soon be launched. The drug is an oral use selective sphingosine-1-phosphate receptor modulator, particularly being developed for the use in multiple sclerosis (MS) condition. Siponimod works by trapping B cells and T cells in body's lymph...
View full press release